8-K: 2seventy bio Announces Strategic Shift, Sells R&D Pipeline to Regeneron, Focuses on Abecma

2seventy bio will sell its oncology and autoimmune research programs to Regeneron and focus on the commercialization of Abecma, resulting in significant cost savings and a leadership transition.

Summary

• 2seventy bio has entered into an asset purchase agreement with Regeneron to sell its oncology and autoimmune research and development programs, clinical manufacturing capabilities, and related platform technologies.
• Regeneron will pay 2seventy bio $5 million upfront, a $10 million milestone payment upon regulatory approval of the first product candidate, and royalties on net sales of commercialized products.
• 2seventy bio will focus on the commercialization and development of Abecma, its CAR T-cell therapy for multiple myeloma, in partnership with Bristol Myers Squibb.
• The company expects annual cost savings of approximately $150 million in 2024 and $200 million in 2025, including one-time restructuring costs of about $8 million.
• A workforce reduction of approximately 14% is expected to be substantially complete by the end of the second quarter of 2024.
• Nick Leschly will resign as CEO and become Chairman of the Board, while William Baird will become the new CEO, and Victoria Eatwell will become the CFO, all effective upon the closing of the asset sale.
• The company anticipates its cash runway will extend beyond 2027.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the strategic shift and cost-cutting measures are positive for long-term financial stability, the sale of the R&D pipeline and workforce reduction are negative indicators. The focus on Abecma is a positive, but the overall sentiment is neutral to slightly negative due to the significant changes and potential risks.

Positives

• The sale of the R&D pipeline to Regeneron provides an immediate cash infusion of $5 million and potential future milestone payments and royalties.
• Focusing on Abecma allows the company to concentrate resources on a product with existing market presence and growth potential.
• The restructuring is expected to result in significant cost savings, improving the company's financial position.
• The company's cash runway is extended beyond 2027, providing financial stability.
• The transition of the R&D team to Regeneron ensures the continuation of important research and development work.
• The company is taking steps to return Abecma to commercial growth in 2024, including a potential third-line launch.

Negatives

• The company is undergoing a 14% workforce reduction, which will result in one-time costs of approximately $8 million.
• The company is selling its research and development pipeline, which may limit future growth opportunities beyond Abecma.
• The company is incurring costs associated with the restructuring and workforce reduction.
• The company is losing its Chief Scientific Officer, Philip Gregory, to Regeneron.

Risks

• The closing of the asset sale is subject to customary closing conditions, including regulatory approvals and landlord consent.
• The company may not achieve the expected cost savings or commercial success with Abecma.
• The company may incur additional costs not currently contemplated due to events associated with the restructuring.
• The company's future success is heavily reliant on the performance of Abecma.
• The company is dependent on its partnership with Bristol Myers Squibb for the commercialization of Abecma.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from forward-looking statements.

Future Outlook

2seventy bio will focus on the commercialization and development of Abecma, with a streamlined team and a dramatically different cost structure and financial profile. The company expects to work closely with its partners at BMS to support a potential third-line launch of Abecma later this year and a return to growth for the commercial business. The company anticipates its cash runway will extend beyond 2027.

Management Comments

• Nick Leschly stated that the decision to reshape 2seventy was driven by a series of challenging realities, but it has resulted in an outcome that is right for patients, employees, and shareholders.
• Chip Baird said that the company will be sharply focused on Abecma, with a streamlined team and a dramatically different cost structure and financial profile.
• Chip Baird also stated that the company believes this approach will give 2seventy the financial runway to continue to work closely with our partners at BMS to support a potential third-line launch of Abecma later this year and a return to growth for the commercial business.

Industry Context

This announcement reflects a strategic shift in the biotech industry, where companies are increasingly focusing on core assets and streamlining operations to achieve profitability. The sale of the R&D pipeline to Regeneron indicates a trend of larger pharmaceutical companies acquiring promising technologies and talent from smaller biotech firms. The focus on Abecma aligns with the growing interest in CAR T-cell therapies for cancer treatment.

Comparison to Industry Standards

• The decision to sell the R&D pipeline and focus on a single product is similar to strategies employed by other biotech companies facing financial challenges, such as bluebird bio, which also restructured to focus on its core assets.
• The cost-cutting measures, including workforce reductions, are common in the biotech industry when companies need to extend their cash runway and achieve profitability.
• The collaboration with Bristol Myers Squibb for Abecma is a typical model for commercializing complex therapies, similar to other partnerships in the CAR T-cell space, such as Novartis and Kite Pharma.
• The upfront payment and potential milestone payments and royalties from Regeneron are standard terms in asset purchase agreements in the biotech industry, comparable to deals seen in other similar transactions.
• The leadership transition is not uncommon in companies undergoing significant strategic changes, with new executives often brought in to execute the new strategy.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the restructuring, but the long-term focus on Abecma and cost savings could be beneficial.
• Employees will be impacted by the workforce reduction, with approximately 14% of the workforce being laid off.
• Employees transitioning to Regeneron will continue their work in research and development.
• Customers (patients) may benefit from the increased focus on Abecma and its potential expansion into earlier lines of therapy.
• Suppliers may experience changes in demand due to the restructuring and focus on Abecma.
• Creditors may be impacted by the company's financial restructuring and cost-cutting measures.

Next Steps

• Complete the asset sale to Regeneron.
• Implement the workforce reduction.
• Focus on the commercialization and development of Abecma.
• Work with BMS to support a potential third-line launch of Abecma.
• Continue to support the quality control of the lentiviral vector (LVV) manufacturing for Abecma.
• Transition to suspension LVV manufacturing.
• Enter into ancillary agreements with Regeneron, including a transition services agreement, a license agreement, and sublease agreements.

Key Dates

Keywords

2seventy bio, Regeneron, Abecma, CAR T-cell therapy, oncology, autoimmune, asset sale, restructuring, workforce reduction, milestone payment, royalties, cost savings, multiple myeloma, Bristol Myers Squibb, leadership transition